Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes

Leukemia

Volumn 13, Issue 4, 1999, Pages 553-557

  Zwierzina, H ^a,e   Anderson, J E ^b   Rollinger Holzinger, I ^a   Torok Storb, B ^b   Nuessler, V ^c   Lyman, S D ^d  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b Fred Hutchinson Cancer Research Center   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d AMGEN INC   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

FLT3 ligand; Myelodysplastic syndromes (MDS); Serum level

Indexed keywords

FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; TYROSINE KINASE RECEPTOR;

AGE; ARTICLE; BLOOD CELL COUNT; BLOOD LEVEL; BONE MARROW; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA;

EID: 0032916076     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401378     Document Type: Article

References (31)

1. Koeffler Ph. Myelodysplastic syndromes (preleukemia). Semin Hematol 1986; 4: 284-291.
2. Bennett J, Catovsky D, Flandrin G, Daniel MT, Galton DAG, Gralnick H, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 1: 189-199.
3. Yunis J, Rydell RE, Oken MM, Arnesen M, Mayer M, Lobell M. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood 1986; 67: 1721-1730.
4. Mufti GJ, Stevens J, Oscier D, Hamblin TG. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1986; 59: 425-432.
5. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737-743.
6. Willemze R, van der Lely N, Zwierzina H, Suciu S, Solbu G, Gerhartz H, Labar B, Visani G, Peetermans ME, Jacobs A, Stryckmans P, Fenaux P, Haak HL, Ribeiro MM, Baumelou E, Baccarani M, Mandelli F, Jaksic B, Louwagie A, Thyss A, Hayat M, de Cataldo F, Stern AC, Zittoun R on behalf of the EORTC Leukemia Cooperative Group. A randomized phase I/II multicenter study of recombinant human GM-CSF therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann Hematol 1992; 64: 173-180.
7. Ganser A, Völkers B, Greher J, Ottmann O, Waltherm F, Becherm R, Bergmann L, Schulz G, Hoelzer D. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes - a phase I/II trial. Blood 1989; 73: 31-36.
8. Willemze R, Fenaux P, Gerhartz H, Zwierzina H, de Witte T, Stryckmans P, Labar B, Sklenar I, Suciu S, Solbu G, Dardenne M, Hoffbrand V, Jacobs A, Josten C, Zittoun R. A randomized phase I/II multicenter study of rhlL-3 in patients with myelodysplastic syndromes at relatively low risk of developing leukemia. Blood 1992; 80 (Suppl 1): 86a.
9. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and pro-genitor cell-enriched populations. Cell 1991; 65: 1143-1148.
10. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, Witte L, Borowitz MJ, Civin Cl, Small D. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996; 87: 1089-1096.
11. Lyman SD, James L, Van den Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FF, Maraskovsky E, Farrah F, Foxworthe D, Williams DE, Beckmann MP. Molecular cloning of the ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75: 1157-1167.
12. + bone marrow progenitor cells in vitro. Blood 1996; 87: 1317-1323.
13. Piacibello W, Fubine L, Sanavio F, Brizzi MF, Severino A, Garetto L, Stacchini A, Pegoraro L, Aglietta M. Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1995; 86: 4105-4114.
14. Tuzuner N, Cox C, Rowe JM, Bennett JM. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. Leukemia Res 1994; 18: 559-564.
15. Lyman SD, Seaberg M, Hanna R, Zappone JD, Brasel K, Abkowitz JL, Prchal JT, Schultz JC, Shahidi NT. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 1995; 86: 4091-4096.
16. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985; 313: 745-749.
17. Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 1986; 68: 1178-1183.
18. Fiedler W, Suciu E, Wittlief C, Ostertag W, Hossfeld DK. Mechanisms of growth factor expression in acute myeloid leukemia (AML). Leukemia 1990; 4: 459-464.
19. Budel L, Touw I, Clark S, Löwenberg B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood 1989; 74: 565-571.
20. Zwierzina H, Schollenberger S, Herald M, Schmalzl F, Besemer J. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leukemia Res 1992; 16: 1181-1186.
21. Herald M, Schmalzl F, Zwierzina H. Increased serum interleukin-6 levels in patients with myelodysplastic syndromes. Leukemia Res 1992; 16: 585-588.
22. Lyman SD, Jacobsen SEW. c-kit ligand and flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-1134.
23. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, Sachdev RK, Yaschenkoff Yn, Birkett NC, Williams LR, Satyagal VN, Tung W, Bosselman RA, Mendiaz EA, Langley KE. Identification, purification and biological characterization of hematopoietic stem cell factor from buffalo rat-conditioned medium. Cell 1990; 63: 195-202.
24. McNiece IK, Langley KE, Zsebo KM. Recombinant human stem cell factor synergizes with CM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells in the myeloid and erythroid lineages. Exp Hematol 1991; 19: 226-231.
25. Broxmeyer HE, Cooper S, Lu L, Hangoc C, Anderson D, Cosman D, Lyman SD, Williams DE. Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood 1991; 77: 2142-2149.
26. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335: 88-92.
27. Jacobsen SEW, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The flt3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 1995; 181: 1357-1163.
28. Langley KE, Bennett LC, Wypych J, Yancik SA, Liu XD, Westcott KR, Chang DG, Smith KA, Zsebo KM. Soluble stem cell factor in human serum. Blood 1993; 81: 656-661.
29. Zwierzina H, Bammer T, Rollinger-Holzinger I, Herold M, Fenaux P, Nuessler V, Hoflehner E, Geissler D. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels. Clin Cancer Res 1996; 2: 1031-1038.
30. Lynch D, Andreasen A, Marakovsky E, Whitmore J, Miller R, Schuh J. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature Med 1997; 3: 625-631.
31. Turner AM, Lin NL, Issara Chai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88: 3383-3390.